conjugated Cetuximab (C225), a targeting agent for epidermal growth factor receptor (EGFR) with AuNPs for the treatment of EGFR positive non‐small cell lung cancer (NSCLC).[142] This C225‐AuNPs inhibited proliferation and migration of A549 cells and accelerated apoptosis in A549 cells as compared to treatment with free C225 alone. Here, EGFR is linked to non-small cell lung carcinoma.